Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 2—February 2024
Research

Impact of Meningococcal ACWY Vaccination Program during 2017–18 Epidemic, Western Australia, Australia

Krist Ewe1Comments to Author , Parveen Fathima1, Paul Effler, Carolien Giele, and Peter Richmond
Author affiliations: Wesfarmers Centre of Vaccines and Infectious Diseases, Perth, Western Australia, Australia (K. Ewe, P. Fathima, P. Richmond); Perth Children’s Hospital, Perth (K. Ewe, P. Richmond); Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia (P. Fathima); Communicable Disease Control Directorate, Western Australia Department of Health, Perth (P. Effler, C. Giele); University of Western Australia School of Medicine, Perth (P. Richmond).

Main Article

Figure 5

Invasive meningococcal disease notification rates (per 100,000 population) by population group in Western Australia (Aboriginal vs. non-Aboriginal), 2012–2020, by year (A) and age group (B).

Figure 5. Invasive meningococcal disease notification rates (per 100,000 population) by population group in Western Australia (Aboriginal vs. non-Aboriginal), 2012–2020, by year (A) and age group (B).

Main Article

1These authors contributed equally to this article.

Page created: December 31, 2023
Page updated: January 24, 2024
Page reviewed: January 24, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external